Patent ID: 9629834
Date: 2017-04-25
CPC Classifications: A61K,A61P

Claim:
1. A method for treatment of a disease associated with cerebral aneurysm, comprising administering to a subject in need thereof an effective amount of a sphingosine-1-phosphate receptor 1 agonist which is at least one compound selected from the group consisting of 5-{5-[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]-1,2,4-oxadiazol-3-yl}-1H-benzimidazole or a pharmaceutically acceptable salt thereof, 1-[(7-{[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof, 2-amino-2-[2-[4-[3-(benzyloxy)phenylsulfanyl]-2-chlorophenyl]ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof, and 1-[4-[N-[4-cyclohexyl-3-(trifluoromethyl)benzyloxy]-1(E)-iminoethyl]-2-ethylbenzyl]azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof.